These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 6304342)
21. Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. Gorga JC; Horejsí V; Johnson DR; Raghupathy R; Strominger JL J Biol Chem; 1987 Nov; 262(33):16087-94. PubMed ID: 2824477 [TBL] [Abstract][Full Text] [Related]
22. Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1). Klein G; Zeuthen J; Eriksson I; Terasaki P; Bernoco M; Rosén A; Masucci G; Povey S; Ber R J Natl Cancer Inst; 1980 Apr; 64(4):725-38. PubMed ID: 6245297 [TBL] [Abstract][Full Text] [Related]
23. Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins. Strnad BC; Neubauer RH; Rabin H; Mazur RA J Virol; 1979 Dec; 32(3):885-94. PubMed ID: 92577 [TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. Murray RJ; Wang D; Young LS; Wang F; Rowe M; Kieff E; Rickinson AB J Virol; 1988 Oct; 62(10):3747-55. PubMed ID: 2843672 [TBL] [Abstract][Full Text] [Related]
25. Production of human monoclonal antibodies by the epstein-barr virus method. Steinitz M Methods Mol Biol; 2014; 1060():111-22. PubMed ID: 24037838 [TBL] [Abstract][Full Text] [Related]
26. CD4+ proliferative T-cell clones reactive to autologous Epstein-Barr virus-transformed B cells (EBV-LCL) can be restricted by HLA class I molecules. Chen BP; DeMars R; Hank JA; Sondel PM Cell Immunol; 1988 Sep; 115(2):363-72. PubMed ID: 2842068 [TBL] [Abstract][Full Text] [Related]
27. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients. Hauber I; Gulle H; Wolf HM; Maris M; Eggenbauer H; Eibl MM J Exp Med; 1995 Apr; 181(4):1411-23. PubMed ID: 7699327 [TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus-induced membrane antigens: immunochemical characterization of Triton X-100 solubilized viral membrane antigens from EBV-superinfected Raji cells. Qualtiere LF; Pearson GR Int J Cancer; 1979 Jun; 23(6):808-17. PubMed ID: 89099 [TBL] [Abstract][Full Text] [Related]
29. CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis. Wilson AD; Redchenko I; Williams NA; Morgan AJ Int Immunol; 1998 Aug; 10(8):1149-57. PubMed ID: 9723701 [TBL] [Abstract][Full Text] [Related]
30. Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line. Gras GS; Dormont D J Virol; 1991 Jan; 65(1):541-5. PubMed ID: 1845908 [TBL] [Abstract][Full Text] [Related]
31. Requirement of Ia-positive accessory cells in the MLR response against class II antigen on human B cell tumor line. Yamamoto M; Yano A J Immunol; 1985 Dec; 135(6):3887-96. PubMed ID: 2999233 [TBL] [Abstract][Full Text] [Related]
32. A new Epstein-Barr virus negative Burkitt's lymphoma derived cell-line. I. Analysis of cell surface markers and abnormal expression of HLA antigens. Kalil J; Fellous M; Tanigaki N; Rosa F; Pagniez C; Herzog C; Dastot H; Lenoir G Tissue Antigens; 1982 Jul; 20(1):47-62. PubMed ID: 6289490 [TBL] [Abstract][Full Text] [Related]
33. EBV transformed B cell lines present to antigen specific T cell clones determinants different from those recognized by antibody in an HLA-DR linked restricted fashion. Chu E; Umetsu D; Yunis E; Geha RS Hum Immunol; 1983 Nov; 8(3):217-26. PubMed ID: 6196340 [TBL] [Abstract][Full Text] [Related]
34. Human T-cell hybrids with HLA-restricted proliferative response to Epstein-Barr virus-infected B cells. Gallagher G; Stimson WH Immunology; 1984 Dec; 53(4):611-21. PubMed ID: 6209205 [TBL] [Abstract][Full Text] [Related]
35. Surface marker characterization of EBV target cells in normal blood and tonsil B lymphocyte populations. Aman P; Gordon J; Lewin N; Nordström M; Ehlin-Henriksson B; Klein G; Carstensson A J Immunol; 1985 Oct; 135(4):2362-7. PubMed ID: 2993411 [TBL] [Abstract][Full Text] [Related]
36. Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren's Syndrome. Sanosyan A; Daien C; Nutz A; Bollore K; Bedin AS; Morel J; Zimmermann V; Nocturne G; Peries M; Guigue N; Gottenberg JE; Van de Perre P; Mariette X; Tuaillon E Front Immunol; 2019; 10():1153. PubMed ID: 31191532 [TBL] [Abstract][Full Text] [Related]
37. HLA type of EBV-transformed human B cell lines. Hurley CK; Johnson AH Curr Protoc Immunol; 2001 May; Appendix 1():Appendix 1G. PubMed ID: 18432643 [TBL] [Abstract][Full Text] [Related]
38. Progenitor and pre-B lymphocytes transformed by Epstein-Barr virus. Ernberg I; Falk K; Hansson M Int J Cancer; 1987 Feb; 39(2):190-7. PubMed ID: 3026970 [TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies against Epstein-Barr virus transformed B lymphocytes from a CLL patient. Guha AK; Ghose T; Luner SJ; Nolido-Cruz H; Uniyal S; Rajaraman R; Fernandez LA; Lee SS; Lee CL Hybridoma; 1990 Apr; 9(2):119-32. PubMed ID: 2161403 [TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Wang F; Gregory CD; Rowe M; Rickinson AB; Wang D; Birkenbach M; Kikutani H; Kishimoto T; Kieff E Proc Natl Acad Sci U S A; 1987 May; 84(10):3452-6. PubMed ID: 3033649 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]